The Role of Plasma Creatine Phosphokinase (CPK) Level in Prediction of Response to Methotrexate for Ectopic Pregnancy
,
Abstract
Objective: To evaluate the plasma creatine phosphokinase (CPK) level after injection of methotrexate (MTX) as a predictor of treatment success in ectopic pregnancy (EP).
Materials and methods: One hundred women treated with single dose of methotrexate for ectopic pregnancy were evaluated in a prospective study, for CPK and ß-subunit of human chorionic gonadotropin (ß-hCG) levels. They received intramuscular MTX at a dose of 50 mg/m2. The day of injection was considered as day 1 (D1). CPK level on the day of Methotrexate injection was compared between success group who were treated by a single MTX injection, and the unsuccessful groupwho were treated by two or three MTX injections or by surgery.
Results: The success rate of single dose of MTX injection was 78 (78%). The mean of CPK was higher in success group than unsuccessful group. (86 ± 10.7 vs. 73 ± 11.8), the difference was significant
(p = 0.04). The mean of ß-hCG was significantly lower in treatment success group than unsuccessful group (1421.3 ± 443.6 vs. 1925.6 ± 185.4, p = 0.01).
Conclusion: The success of single dose of MTX treatment in ectopic pregnancy may be predicted by CPK levels and the higher levels of CPK may be useful for detecting of patients with successful response to MTX.
Develioglu OH, Askalli C, Uncu G, Samli B, Daragenli O. Evaluation of serum creatine kinase in ectopic pregnancy with reference to tubal status and histopathology. BJOG 2002;109:121-8.
Birkhahn RH, Gaeta TJ, Leo PJ, Bove JJ. The utility of maternal creatine kinase in the evaluation of ectopic pregnancy. Am J Emerg Med 2000;18,695-7.
Barnhart KT. Clinical practice. Ectopic pregnancy. N Engl J Med 2009;361:379-87.
Soundravally R, Soundara Raghavan S, Selvaraj N. Serum creatine kinase as a predictor of tubal ectopic pregnancy. Int J Gynaecol Obstet 2007;98:253-4.
Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta analysis comparing ‘‘single dose’’ and ‘‘multidose’’ regimens. Obstet Gynecol 2003;101:778-84.
Lipscomb GH, Givens VA, Meyer NL, Bran D. Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy. Fertil Steril 2004;81:1221-4.
Kriebs JM, Fahey JO. Ectopic pregnancy. J Midwifery Womens Health 2006;51:431-9.
Condous G. Ectopic pregnancy-risk factors and diagnosis. Aust Fam Physician 2006;35:854-7.
Hoover KW, Tao G, Kent CK. Trends in the diagnosis and treatment of ectopic pregnancy in the United States. Obstet Gynecol 2010;115:495-502.
Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta analysis comparing ‘‘single dose’’ and ‘‘multidose’’ regimens. Obstet Gynecol 2003;101:778-84.
Lipscomb GH, Givens VA, Meyer NL, Bran D.
Previous ectopic pregnancy as a predictor of failure of systemic methotrexate therapy. Fertil Steril 2004; 81:1221-4.
Lipscomb GH, Givens VM, Meyer NL, Bran D. Comparison of multidose and single-dose methotrexate protocols for the treatment of ectopic pregnancy. Am J Obstet Gynecol 2005;192:1844-8.
Colins J, Barnhart KT. Establishing a human chorionic gonadotropin cut off to guide methotrexate treatment of ectopic pregnancy: a systematic review. Fertil Steril 2007; 87:481-4.
Lipscomb GH, McCord ML, Stovall TG, Huff G, PorteraSG, LingFW. Predictors of success of methotrexate treatment in women with tubal ectopic pregnancies. N Engl J Med 1999;341:1974-8
DeveliogluOH, Askalli C, Uncu G, SamliB,Daragenli O. Evaluation of serum creatine kinase in ectopic pregnancy with reference to tubal status and histopathology. BJOG 2002;109:121-8.
Birkhahn RH, Gaeta TJ, Paraschiv D, Bove JJ, Suzuki T, Katoh H, et al. Serum levels of myoglobin, creatine phosphokinase, and smooth muscle heavy-chain myosin in patients with ectopic pregnancy. Ann Emerg Med 2001; 38: 628-32.
Cartwright J, Duncan WC, Critchley HO, Horne AW. Serum biomarkers of tubal ectopic pregnancy: current candidates and future possibilities. Reproduction 2009; 138: 9-22.
Nowak-Markwitz E, Michalak M, Olejnik M, Spaczynski M. Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy. Fertil Steril 2009;92:1203-7.
Birkhahn RH, Gaeta TJ, Leo PJ, Bove JJ. The utility of maternal creatine kinase in the evaluation of ectopic pregnancy. Am J Emerg Med 2000; 18:695-7.
Katsikis I, Rousso D, Farmakiotis D, Kourtis A, Diamanti-Kandarakis E, Zournatzi-Koiou V, et al. Creatine phosphokinase in ectopic pregnancy revisited: significant diagnostic value of its MB and MM isoenzyme fractions. Am J Obstet Gynecol 2006;194:86-91.
Gnisci A, Rua S, Courbiere B, Cravello L, Gamerre M, Agostini A Plasma creatine phosphokinase level may predict successful treatment after a single injection of methotrexate for ectopic pregnancy. Fertil Steril 2011;95:2131-3.
Asgharnia M, Faraji R, Mirblouk F, AtrkarRoshan Z, Parvizi A. Evaluation of serum creatine phosphokinase in diagnosis of tubal ectopic pregnancy compared with intrauterine pregnancy and threatened abortion.
Iranian Journal of Reproductive Medicine 2012; 10:
-6.
Qasim SM, Trias A, Sachdev R, Kemman E. Evaluation of serum creatine kinase levels in ectopic pregnancy. Fertil Steril 1996;65:443-45.
Vitoratos N, Gregoriou O, Papadias C, et al. Clinical value of creatinine kinase in the diagnosis of ectopic
pregnancy. Gynecol Obstet Invest 1998;46:80-3.
| Files | ||
| Issue | Vol 10, No 2 (June 2016) | |
| Section | Original Articles | |
| Keywords | ||
| Methotrexate CPK Ectopic Pregnancy | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
